Long-Term Retarded Release for the Proteasome Inhibitor Bortezomib through Temperature-Sensitive Dendritic Glycopolymers as Drug Delivery System from Calcium Phosphate Bone Cement

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung



For the local treatment of bone defects, highly adaptable macromolecular architectures are still required as drug delivery system (DDS) in solid bone substitute materials. Novel DDS fabricated by host-guest interactions between beta-cyclodextrin-modified dendritic glycopolymers and adamantane-modified temperature-sensitive polymers for the proteasome inhibitor bortezomib (BZM) is presented. These DDS induce a short- and long-term (up to two weeks) retarded release of BZM from calcium phosphate bone cement (CPC) in comparison to a burst release of the drug alone. Different release parameters of BZM/DDS/CPC are evaluated in phosphate buffer at 37 degrees C to further improve the long-term retarded release of BZM. This is achieved by increasing the amount of drug (50-100 mu g) and/or DDS (100-400 mu g) versus CPC (1 g), by adapting the complexes better to the porous bone cement environment, and by applying molar ratios of excess BZM toward DDS with 1:10, 1:25, and 1:100. The temperature-sensitive polymer shells of BZM/DDS complexes in CPC, which allow drug loading at room temperature but are collapsed at body temperature, support the retarding long-term release of BZM from DDS/CPC. Thus, the concept of temperature-sensitive DDS for BZM/DDS complexes in CPC works and matches key points for a local therapy of osteolytic bone lesions.


FachzeitschriftMacromolecular rapid communications
PublikationsstatusVeröffentlicht - Juli 2021

Externe IDs

PubMed 34048124
Scopus 85106560636
ORCID /0000-0002-4531-691X/work/148607980



  • Calcium phosphate cements, Dendritic glycopolymers, Drug delivery systems, Proteasome inhibitors, Sensitive polymers, Temperature&#8208